Neuroblastoma: all 634 studies

Page 2 of 7. Open to participants first (122), then studies with results posted, then the rest; newest registration first within each.

• GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With NeuroblastomaRecruitingNCT03294954Phase 1
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingNCT03126916Phase 3
• International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARERecruitingNCT03088020
• Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
• A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic PheochromocytomaAvailableNCT03015844
• Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk NeuroblastomaRecruitingNCT02605421Phase 2
• Pediatric Precision Laboratory Advanced Neuroblastoma TherapyRecruitingNCT02559778Phase 2
• Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective StudyRecruitingNCT02558244
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsRecruitingNCT02508038Phase 1
• Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingNCT02013336Phase 1
• The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK CellsEnrolling by invitationNCT01868490Phase 1/2
• Reduced Intensity Haploidentical BMT for High Risk Solid TumorsRecruitingNCT01804634Phase 2
• High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingNCT01704716Phase 3
• Expanded Access Protocol Using 131I-MIBGAvailableNCT01590680
• Neuroblastoma Biology StudyRecruitingNCT01587300
• 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use ProtocolAvailableNCT01370330
• 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access ProtocolAvailableNCT01163383
• Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesRecruitingNCT01109394
• Molecular Analysis Of Solid TumorsRecruitingNCT01050296
• Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsRecruitingNCT01005654
• Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical OutcomeRecruitingNCT00588068
• Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaRecruitingNCT00107289Phase 2
• Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk NeuroblastomaCompletedNCT05373901Phase 1Results posted
• Real World Data Collection Pediatric Neuroblastoma Treated With LorlatinibTerminatedNCT04753658Results posted
• Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaTerminatedNCT04751383Phase 1Results posted
• A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedNCT04730349Phase 1/2Results posted
• Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk NeuroblastomaTerminatedNCT04560166Phase 2Results posted
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedNCT04544995Phase 1Results posted
• Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young AdultsTerminatedNCT04530487Phase 2Results posted
• Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingNCT04385277Phase 2Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaCompletedNCT04238819Phase 1/2Results posted
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminatedNCT04029688Phase 1/2Results posted
• Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor CancersTerminatedNCT03860207Phase 1/2Results posted
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaActive, not recruitingNCT03794349Phase 2Results posted
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsCompletedNCT03709680Phase 2Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaActive, not recruitingNCT03503864Phase 2Results posted
• Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric PatientsTerminatedNCT03458728Phase 1/2Results posted
• MIBG With Dinutuximab +/- VorinostatCompletedNCT03332667Phase 1Results posted
• Oral Liquid 13-cis-retinoic Acid (13-CRA)CompletedNCT03291080Phase 1/2Results posted
• 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesTerminatedNCT03275402Phase 2/3Results posted
• Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)CompletedNCT03273712Phase 2Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213691Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)CompletedNCT03107988Phase 1Results posted
• Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma PatientsCompletedNCT02924324Not applicableResults posted
• High-Risk Neuroblastoma Chemotherapy Without G-CSFCompletedNCT02786719Not applicableResults posted
• A Phase I Trial of Anti-GD2 T-cells (1RG-CART)CompletedNCT02761915Phase 1Results posted
• Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma PatientsTerminatedNCT02693171Results posted
• Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)TerminatedNCT02624388Phase 2Results posted
• Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial SarcomaCompletedNCT02452554Phase 2Results posted
• Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine TumorsCompletedNCT02441062Phase 2Results posted
• Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in RemissionCompletedNCT02395666Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• GA-68 DOTA-TOC of Somatostatin Positive MalignanciesTerminatedNCT02177773Phase 1/2Results posted
• Molecular-Guided Therapy for Childhood CancerCompletedNCT02162732Not applicableResults posted
• Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory NeuroblastomaCompletedNCT02139397Phase 1/2Results posted
• Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk NeuroblastomaCompletedNCT02100930Not applicableResults posted
• Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid TumorsTerminatedNCT02100891Phase 2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• A Phase I/II Study of [124I]mIBG PET/CT in NeuroblastomaCompletedNCT02043899Phase 1/2Results posted
• 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With VorinostatCompletedNCT02035137Phase 2Results posted
• Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With CancerTerminatedNCT01987596Phase 3Results posted
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/2Results posted
• Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CTCompletedNCT01869725Phase 2Results posted
• Therapy for Children With Advanced Stage NeuroblastomaCompletedNCT01857934Phase 2Results posted
• Molecular-Guided Therapy for Relapsed and Refractory Childhood CancerCompletedNCT01802567Not applicableResults posted
• Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT01798004Phase 1Results posted
• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaCompletedNCT01767194Phase 2Results posted
• Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and NeuroblastomaTerminatedNCT01747876Phase 1Results posted
• Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid TumorsCompletedNCT01619865Phase 1/2Results posted
• Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedNCT01606878Phase 1Results posted
• Study of MLN8237 in Combination With Irinotecan and TemozolomideCompletedNCT01601535Phase 1/2Results posted
• ch14.18 Pharmacokinetic Study in High-risk NeuroblastomaCompletedNCT01592045Phase 1/2Results posted
• Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed NeuroblastomaTerminatedNCT01505608Phase 1/2Results posted
• Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and NeuroblastomaCompletedNCT01492673Phase 2Results posted
• Safety and Efficacy Study of TPI-287 in Neuroblastoma and MedulloblastomaTerminatedNCT01483820Phase 1/2Results posted
• Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory NeuroblastomaCompletedNCT01460901Phase 1Results posted
• A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal NeuroblastomaTerminatedNCT01440283Phase 2Results posted
• Molecular Guided Therapy for Refractory or Recurrent NeuroblastomaCompletedNCT01355679Not applicableResults posted
• Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory NeuroblastomaCompletedNCT01334515Phase 2Results posted
• High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed NeuroblastomaCompletedNCT01313936Phase 1Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone MarrowCompletedNCT01183897Phase 2Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk NeuroblastomaTerminatedNCT01183884Phase 2Results posted
• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk NeuroblastomaCompletedNCT01183429Phase 2Results posted
• High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell TransplantationCompletedNCT01183416Phase 2Results posted
• Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With IsotretinoinCompletedNCT01175356Phase 1Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted

← Neuroblastoma overview